Ownership and insider activity for MeiraGTx Holdings plc (MGTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers.
Price
| Price | $12.76 |
| Market Cap | $1.2B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.5M | $8.5M | $68.1M | $227.2M | $209.5M | $137.7M | $115.5M | $129.6M | $103.7M | $65.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $37.1M | $55.4M | $35.0M | $29.0M | $23.4M | $10.6M | $18.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $385000 | 0 |
| Total Current Assets | $19.1M | $11.5M | $74.7M | $269.0M | $272.6M | $183.2M | $154.3M | $159.6M | $123.5M | $91.8M |
| Property, Plant & Equipment | $3.0M | $14.3M | $22.0M | $52.9M | $87.1M | $126.3M | $154.1M | $156.2M | $135.7M | $141.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $777655 | $3.0M | $2.6M | $2.1M | $1.1M | $821000 | $578000 |
| Total Assets | $22.6M | $25.9M | $96.9M | $323.9M | $363.7M | $320.2M | $318.2M | $326.7M | $269.8M | $244.4M |
| Accounts Payable | $1.5M | $7.1M | $3.0M | $3.8M | $7.1M | $15.3M | $16.6M | $16.0M | $23.6M | $10.1M |
| Short-term Debt | 0 | $1.4M | 0 | $1.7M | $2.6M | 0 | 0 | 0 | 0 | $24.6M |
| Total Current Liabilities | $6.0M | $21.4M | $15.5M | $49.2M | $54.1M | $68.1M | $82.1M | $67.1M | $60.8M | $122.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $71.0M | $72.1M | $73.2M | $49.7M |
| Total Liabilities | $39.7M | $73.2M | $15.8M | $133.1M | $125.1M | $134.8M | $200.5M | $188.6M | $201.9M | $250.2M |
| Retained Earnings | -$34.4M | -$65.4M | -$148.3M | -$203.0M | -$261.0M | -$340.6M | -$470.2M | -$554.2M | -$702.0M | -$816.2M |
| Total Equity | -$17.1M | -$47.4M | $81.1M | $190.8M | $238.6M | $185.4M | $117.7M | $138.2M | $67.8M | -$5.8M |
| Total Debt | $11473 | $1.5M | $34296 | $23.2M | $22.2M | $23.7M | $92.2M | $89.3M | $84.8M | $88.7M |
| Net Debt | -$17.5M | -$7.0M | -$68.0M | -$204.1M | -$187.3M | -$114.0M | -$23.3M | -$40.3M | -$18.9M | $22.8M |
| Working Capital | $13.0M | -$9.9M | $59.2M | $219.8M | $218.4M | $115.1M | $72.3M | $92.5M | $62.7M | -$30.8M |
Financial Health
| Debt / Equity | 0.52 |
| Current Ratio | 3.76 |
Profitability
| Return on Equity | 284.38% |
| Return on Invested Capital | 52.45% |
| Return on Assets | 19.92% |
| Gross Margin | 97.19% |
| Operating Margin | 46.30% |
| Net Margin | 19.87% |
Explore sector: Healthcare · Biotechnology
More sections of MGTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks